Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Patel, MR; Mahaffey, KW; Garg, J; Pan, G; Singer, DE; Hacke, W; Breithardt, G; Halperin, JL; Hankey, GJ; Piccini, JP; Becker, RC; Nessel, CC; Paolini, JF; Berkowitz, SD; Fox, KA; Califf, RM; ROCKET AF Investigators.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med. 2011; 365(10):883-891 Doi: 10.1056/NEJMoa1009638 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Study Group Members Med Uni Graz:: Pilger Ernst
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin. Methods In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism. Results In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P < 0.001 for noninferiority). In the intention-to-treat analysis, the primary end point occurred in 269 patients in the rivaroxaban group (2.1% per year) and in 306 patients in the warfarin group (2.4% per year) (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P < 0.001 for noninferiority; P = 0.12 for superiority). Major and nonmajor clinically relevant bleeding occurred in 1475 patients in the rivaroxaban group (14.9% per year) and in 1449 in the warfarin group (14.5% per year) (hazard ratio, 1.03; 95% CI, 0.96 to 1.11; P = 0.44), with significant reductions in intracranial hemorrhage (0.5% vs. 0.7%, P = 0.02) and fatal bleeding (0.2% vs. 0.5%, P = 0.003) in the rivaroxaban group. Conclusions In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials. gov number, NCT00403767.)
Find related publications in this database (using NLM MeSH Indexing): Administration, Oral -; Aged -; Aged, 80 and over -; Anticoagulants - adverse effects Anticoagulants - therapeutic use; Atrial Fibrillation - complications Atrial Fibrillation - drug therapy; Double-Blind Method -; Embolism - epidemiology Embolism - prevention & control; Female -; Hemorrhage - chemically induced; Humans -; Intention to Treat Analysis -; Male -; Middle Aged -; Morpholines - administration & dosage Morpholines - adverse effects Morpholines - therapeutic use; Stroke - epidemiology Stroke - prevention & control; Thiophenes - administration & dosage Thiophenes - adverse effects Thiophenes - therapeutic use; Treatment Outcome -; Warfarin - administration & dosage Warfarin - adverse effects Warfarin - therapeutic use